Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C.
In the last thirty years, factor VIII concentrates have been the mainstay of hemophilia treatment, first as wet cryoprecipitate and later as dry concentrates commercially available. The evidence of a high risk of blood-born virus transmission by these products provoked the development of new methods...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ordem dos Médicos
1992-12-01
|
| Series: | Acta Médica Portuguesa |
| Online Access: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307 |